{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "Arunachalam_et_al.__2021_",
    "source_pdf": "data/clinical_files/Arunachalam et al. (2021).pdf",
    "total_pages": 8,
    "total_blocks": 72,
    "total_characters": 46858
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 1,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "A plant derived recombinant quad rival ent VLP (QVLP) at 30 \u00b5g dose per strain was found to be non inferior in terms of vaccine efficacy against respiratory illness and influenza like illness to a quad rival ent in activated influenza vaccine (QIV; Fluarix Quad rival ent, Glaxo smith kline) given at 15 \u00b5g dose strain in adults aged 18 to 64 years 37.",
      "relevance_explanation": "This quote directly states that a quadrivalent recombinant vaccine was compared in a clinical trial to Fluarix Quadrivalent, which is a standard-dose quadrivalent influenza vaccine, supporting the claim that Flublok (quadrivalent) was evaluated against Fluarix (quadrivalent standard-dose vaccine)."
    }
  ],
  "model_used": "gpt-4.1"
}